Trasplante de células madre formadoras de sangre con agotamiento de células T alfa/beta de donantes relacionados o no relacionados para enfermedades de la sangre en niños y adultos jóvenes
Trasplante de células madre hematopoyéticas empobrecidas en TCRαβ+ y CD19+ de donantes no emparentados estrechamente compatibles o donantes emparentados haploidénticos para enfermedades hematológicas en niños y adultos jóvenes
This study is being done to see if the investigators can take peripheral blood stem cells from either an adult family member or a closely matched unrelated donor, and run them through a special lab instrument to remove alpha/beta T cells and B cells and then give them to the patient to treat disease. This is an experimental way of doing a hematopoietic stem cell transplant (HSCT). The investigators want to see if the new stem cells will grow without bad graft vs. host disease (GVHD). This treatment approach is experimental in the United States.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This single institution, phase I clinical trial will determine the safety and feasibility of employing T-cell receptor (TCR) αβ+ and CD19+ (Cluster of Differentiation) depleted hematopoietic stem cell transplantation (HSCT) using peripheral blood stem cells (PBMC) from closely matched unrelated donors or haploidentical donors to treat non-malignant hematologic diseases in children and young adults. Allogeneic hematopoietic stem cell transplantation has become a curative option for children and adolescents with a variety of otherwise fatal conditions. To reduce the incidence and severity of graft-versus-host disease (GVHD) associated with allogeneic hematopoietic stem cell transplantation, donor grafts are depleted of T cells, either using CD34+ selection or CD3+/CD19+ depletion of grafts. However, these selection processes also deplete the graft of protective cell subsets, such as γδ T cells, natural killer (NK) cells, monocytes and dendritic cells, which play important roles in the immune response to infectious agents. Moreover, the presence of NK cells and γδ T cells in donor grafts is associated with more rapid immune reconstitution after HSCT transplantation. In order to retain these protective immune cell subsets, this trial will use a novel, highly selective graft engineering process using the Miltenyi CliniMACS system that selectively depletes αβ-T cells and B cells that are responsible for GVHD and Epstein Barr Virus (EBV)-related post-transplantation lymphoproliferative disorder, respectively. Prior to transplantation, patients will be treated with a conditioning regimen, specific for the original disorder.
The primary objective of this study is evaluation of the safety and feasibility of HSCT using TCRαβ+/CD19+ depleted hematopoietic stem cells to treat non-malignant hematologic diseases. This will be assessed by evaluating the incidence of graft failure, grade III-IV acute GVHD and chronic GVHD and TRM.
Secondary objectives include the evaluation of immune reconstitution and incidence of post-transplant infections, adverse events, serious adverse events, overall and disease-free survival and the efficiency of graft processing by the CliniMACS System.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Celeste Matsushima
- Número de teléfono: 608-890-8069
Copia de seguridad de contactos de estudio
- Nombre: Jenny Weiland
- Número de teléfono: 608-890-8070
- Correo electrónico: PedsHemOncResearch@lists.wisc.edu
Ubicaciones de estudio
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- Reclutamiento
- American Family Children's Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
No Human leukocyte antigen (HLA) identical sibling available AND
-
NO HLA matched unrelated donor available OR urgent need of HSCT precludes time necessary to search for suitable HLA matched unrelated donor AND
-
Haploidentical donor OR closely matched unrelated donor available and willing to undergo mobilization and apheresis
-
If subject has genetically confirmed inherited bone marrow failure, related donor must be evaluated for this disorder and testing must be negative.
-
If subject has sickle cell disease, donor must be unaffected or have only sickle cell trait
-
Patient must be diagnosed with one of the following diseases or disorders:
-
Hemoglobinopathies
- Sickle Cell Disease for patients ≤ 21 years of age for whom hydroxyurea has been trialed for at least six months, and failed
- Thalassemia Major for patients ≤ 21 years of age
-
Acquired Bone Marrow Failure Syndromes
- Paroxysmal Nocturnal Hemoglobinuria with bone marrow failure
- Myelodysplastic Syndromes (lower risk)
- Severe acquired aplastic anemia
-
Inherited Bone Marrow Failure Syndromes
- Fanconi Anemia
- Diamond Blackfan Anemia
- Dyskeratosis Congenita and related telomere disorders
- Congenital Thrombocytopenia Syndromes
- Severe Congenital Neutropenia
- Shwachman-Diamond Syndrome
-
Inborn Errors of Immunity (IEI) or Primary Immune Regulatory Disorders (PIRD)
- Wiskott-Aldrich syndrome (WAS)
- Chronic granulomatous disease (CGD)
- Severe combined immunodeficiency (SCID)
- Primary hemophagocytic lymphohistiocytosis (HLH)
-
-
Age ≤ 25 years (except patients with hemoglobinopathies)
-
Life Expectancy ≥ 3 months
-
Karnofsky (patients > 16 years)/Lansky (patients ≤ 16 years) index ≥ 60
-
Organ Function Requirements
-
Renal Function
- Creatinine clearance or radioisotope Glomerular Filtration Rate (GFR) greater than or equal to 60 ml/min/1.73m^2
-
Liver Function
- Total bilirubin < 3 mg/dL
- Alanine aminotransferase (ALT)/ Serum glutamic-pyruvic transaminase; synonymous with ALT (SCPT) ≤ 3 x Upper Limit of Normal (ULN) for age
-
Cardiac Function
- Ejection fraction of > 40% by Multiple gated acquisition scan (MUGA) or echocardiogram
-
Pulmonary Function
- No evidence of dyspnea at rest
- No supplemental oxygen requirement
- If measured, carbon monoxide diffusion capacity (DLCO) > 50%
-
-
Willing to use effective birth control method if patient is of reproductive potential
-
Informed consent obtained (patient or legal representative)
Exclusion Criteria:
- Pregnant
- HIV infection
- Uncontrolled, serious active infection at screening
- Significant serious intercurrent illnesses
- Enrollment in any other treatment study that would interfere with the endpoints of this study according to judgement of Principal Investigator (or PI designee).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment arm
Participants will undergo a conditioning regimen, specific for the original disease, After that peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCRαβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems will be administered intravenously on Day 0 to all participants. |
After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems. The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of grade III-IV acute graft-versus-host disease (GVHD)
Periodo de tiempo: 100 days post transplantation
|
Acute GVHD will be assessed and graded according to the Keystone Consensus Criteria for staging and grading of acute graft-versus-host disease. |
100 days post transplantation
|
|
Incidence of extensive chronic GVHD
Periodo de tiempo: up to 2 years
|
Chronic GVHD will be assessed according to the current CIBMTR (Center for International Blood and Marrow Transplant Research) manual reflecting a grading system published by Sullivan KM (Sullivan 1981). |
up to 2 years
|
|
Incidence of graft failure
Periodo de tiempo: up to 2 years after graft
|
Graft failure - defined as failure to achieve ANC > 500 /µL at Day +28 or initial neutrophil engraftment followed by a decline in ANC < 500 /µL that is unresponsive to growth factor therapy (secondary graft failure). |
up to 2 years after graft
|
|
Incidence of Treatment Related Mortality (TRM)
Periodo de tiempo: Day +100 post-HSCT
|
TRM - defined as death from any cause other than disease progression. |
Day +100 post-HSCT
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Supervivencia global (SG)
Periodo de tiempo: hasta 2 años
|
hasta 2 años
|
|
|
Eficiencia del sistema CliniMACS: Porcentaje de células CD34+ viables recuperadas después del procedimiento de agotamiento de TCRαβ+ y CD19+
Periodo de tiempo: hasta 12 meses después del HSCT
|
hasta 12 meses después del HSCT
|
|
|
Correlación entre la incidencia de GVHD y el contenido de haplotipos del receptor tipo inmunoglobulina (KIR) de células asesinas de donantes
Periodo de tiempo: hasta 2 años
|
hasta 2 años
|
|
|
Correlación entre la incidencia de GVHD y el desajuste del receptor similar a inmunoglobulina (KIR)/ligando KIR de células asesinas entre el donante y el receptor.
Periodo de tiempo: hasta 2 años
|
hasta 2 años
|
|
|
Número de participantes con eventos adversos relacionados con la infusión del injerto de HSC
Periodo de tiempo: Día 0
|
Día 0
|
|
|
Incidencia de eventos adversos graves
Periodo de tiempo: hasta 2 años
|
hasta 2 años
|
|
|
CliniMACS system efficiency: log depletion value for CD19/CD20+ B cells after the TCRαβ+ and CD19+ depletion procedure
Periodo de tiempo: Day 0
|
Day 0
|
|
|
CliniMACS system efficiency: log depletion value of TCRαβ+ T cells after the TCRαβ+ and CD19+ depletion procedure
Periodo de tiempo: Day 0
|
Day 0
|
|
|
Time to neutrophil engraftment
Periodo de tiempo: up to 28 days following HSCT
|
The time to neutrophil engraftment is defined as the post-transplant day that is the first of 3 consecutive days with an absolute neutrophil count (ANC) of >500/µL as assessed by CBC. |
up to 28 days following HSCT
|
|
Time to platelet engraftment
Periodo de tiempo: up to 28 days following HSCT
|
The time to platelet engraftment is defined as the post-transplant day that is the first of 3 consecutive days with a platelet count ≥ 20,000/µL as assessed by complete blood count (CBC), without platelet support (transfusion) for 7 days. |
up to 28 days following HSCT
|
|
Percentage donor chimerism using Short Tandem Repeat (STR)
Periodo de tiempo: up to 12 months following HSCT
|
Short tandem repeat (STR) analysis will provide the percentage donor chimerism at specific time points post-transplant. |
up to 12 months following HSCT
|
|
Kinetics of lymphocyte reconstitution via immunophenotyping using flow cytometry
Periodo de tiempo: up to 12 months following HSCT
|
Lymphocyte reconstitution will be assessed at specific time points post-HSCT, expressed as the percentage of white blood cells comprised of T, B and NK cell subsets. |
up to 12 months following HSCT
|
|
CliniMACS system efficiency: number of viable blood cell subsets after the TCRαβ+ and CD19+ depletion procedure
Periodo de tiempo: Day 0
|
Number of viable CD34+ blood stem cells, CD20+ B cells, CD3-CD56+ NK cells, TCRαβ+ T cells, and TCRγδ+ T cells in the HSC graft after the TCRαβ+ and CD19+ depletion procedure |
Day 0
|
|
Event free survival
Periodo de tiempo: up to 1 years
|
An event is defined as death, graft failure or stable mixed chimerism with disease recurrence. |
up to 1 years
|
|
Incidence of symptomatic bacterial/fungal and viral reactivation requiring therapy
Periodo de tiempo: up to 1 year
|
The incidence of infections (symptomatic bacterial/fungal and viral reactivation requiring therapy) will be used as an additional safety measure |
up to 1 year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Christian Capitini, MD, University of Wisconsin, Madison
- Director de estudio: Jacques Galipeau, MD, University of Wisconsin, Madison
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2020-1251
- A536755 (Otro identificador: UW Madison)
- UW19113 (Otro identificador: OnCore ID)
- 2020-1251 (Otro identificador: HS IRB UW Madison)
- NCI-2021-02128 (Identificador de registro: NCI CTRP)
- Protocol Version 6 (Otro identificador: HS-IRB UW Madison)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The Principal Investigator, Sponsor and funding institutions (if applicable) will ensure that all mechanisms used to share data include proper plans and safeguards to protect the rights and privacy of participants who participate in this research.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .